Colorectal cancer is also called "colorectal cancer". The targets of ACTL targeted cellular immunotherapy are carcinoembryonic antigen (CEA), keratin 19 type antigen (CK19, k19, cyfra21-1), prostate specific membrane antigen ( PSMA), a melanoma antigen (MAGE-A3), survivin antigen (Survivin), mucin antigen (MUC-1), Her-2/neu antigen (Her2), tumor-testis antigen 10 (CT10), carbonic acid Anhydrase antigen (G250) and so on. Among them, CEA, CK19 (cyfra21-1), MUC-1 (CA15-3) can be detected in peripheral blood, and other target antigens must be detected by immunohistochemistry with tumor tissue.
As many hospitals cannot fully detect these antigens, those who need it can contact us (contact information: 075586680658-8033). It should be pointed out that the antigen in the blood is negative, but not necessarily the tumor tissue is also negative, and it may be positive. So what checks should be done before receiving ACTL targeted cellular immunotherapy for the colorectal?
1. Blood test
1. Routine blood, urine, stool and other inspections.
2. Blood biochemical index test.
3. Blood tumor markers: carcinoembryonic antigen (CEA), cyfra21-1, CA15-3, CA19-9, etc.

Two, imaging examination
1. Including whole body CT, MRI or PET-CT, PET-CT is recommended for patients with obvious metastasis.
2. Accompanied by liver metastases, MRI examination.
3. Assessment report of the overall physical condition
Hospital medical records.
Four, treatment information
Complete previous and current treatment information

Please provide the above information to the doctor to determine whether it is suitable for ACTL anti-colorectal cancer targeted cellular immunotherapy.